Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7 USD | +1.43% | -4.76% | +22.81% |
30/05 | Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million | MT |
23/05 | Oppenheimer Adjusts Price Target on Viracta Therapeutics to $11 From $13, Maintains Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.81% | 2.71Cr | |
+43.36% | 5.81TCr | |
-5.31% | 4.05TCr | |
+37.52% | 3.9TCr | |
+14.75% | 2.67TCr | |
-12.56% | 2.66TCr | |
-22.45% | 1.9TCr | |
+0.04% | 1.22TCr | |
+25.12% | 1.2TCr | |
+26.04% | 1.19TCr |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.
- Viracta Therapeutics Names Mark Rothera CEO